Eloxx Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. 0.23%62.781.0%$427.65m
AMGNAmgen, Inc. 0.47%238.721.3%$417.35m
BIIBBiogen, Inc. 0.67%289.111.4%$365.42m
ILMNIllumina, Inc. 0.14%328.793.5%$324.02m
VRTXVertex Pharmaceuticals, Inc. 0.67%235.551.9%$275.18m
REGNRegeneron Pharmaceuticals, Inc. 0.74%366.402.6%$218.87m
EXASEXACT Sciences Corp. 4.18%89.4924.0%$205.35m
ITCIIntra-Cellular Therapies, Inc. 0.32%25.519.0%$174.01m
ALXNAlexion Pharmaceuticals, Inc. 0.32%113.372.0%$173.61m
INCYIncyte Corp. 0.88%79.342.5%$136.30m
SRPTSarepta Therapeutics, Inc. -0.44%122.4514.6%$132.46m
AAgilent Technologies, Inc. 0.48%90.041.6%$120.62m
BMRNBioMarin Pharmaceutical, Inc. 0.95%88.394.3%$107.18m
BLUEbluebird bio, Inc. 0.06%95.8814.2%$95.33m
SGENSeattle Genetics, Inc. -0.16%108.506.1%$90.19m

Company Profile

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. It operates through the United States and Israel geographical segments. Its product includes ELX-02, a small molecule drug designed to restore production of full-length functional proteins which treats cystic fibrosis and cystinosis. The company was founded on December 19, 2017 and is headquartered in Waltham, MA.